Year: 2013
Type: article
Abstract: There is no dedicated study on second-line treatment for elderly patients with advanced nonsmall cell lung cancer (NSCLC). We report the results on second-line erlotinib therapy from our previously published phase III study comparing single-agent therapy with platinum-based doublet (carboplatin plus paclitaxel) therapy in 451 elderly patients. Erlotinib was given to patients exhibiting disease progression or experiencing excessive toxicity during first-line therapy, until further progression or unacceptable toxicity. In total, 292 (64.7%) patients received erlotinib as second-line therapy. Initial performance status 0-1, stage IV NSCLC and an Activities of Daily Living score of 6 were independent factors for receiving erlotinib. Median (95% CI) overall survival was 4 (3.2-6.7) versus 6.8 (5.0-8.3) months in the single-agent and doublet arms, respectively (p=0.089). Performance status 0-1, never having smoked, adenocarcinoma and weight loss ≤5% were favourable independent prognostic factors of survival, whereas the randomisation arm had no significant impact. Among the 292 patients who received erlotinib, 60 (20.5%) experienced grade 3-4 toxic effects, the most frequent being rash. Erlotinib as second-line therapy is feasible, leading to efficacy results similar to those obtained in a previous randomised study that was not dedicated to elderly patients, with acceptable toxicity.
Source: European Respiratory Journal
Authors: Elisabeth Quoix, Virginie Westeel, Lionel Moreau, Eric Pichon, Armelle Lavolé, Jérome Dauba, Didier Debieuvre, Pierre Jean Souquet, Laurence Bigay-Game, Eric Dansin, Michel Poudenx, Olivier Molinier, Fabien Vaylet, Denis Moro-Sibilot, Denis Herman, Helene Sennelart, Jean Tredaniel, Bertrand Mennecier, Franck Morin, Laurence Baudrin, Bernard Milleron, Gérard Zalcman
Institutions: Hôpitaux Universitaires de Strasbourg, Centre Hospitalier Universitaire de Besançon, Université de Franche-Comté, Centre Hospitalier Universitaire de Tours, Hôpital Tenon, Centre Hospitalier de Mulhouse, Hospices Civils de Lyon, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Toulouse, Hôpital Larrey, Centre Oscar Lambret, Centre Antoine Lacassagne, Centre Hospitalier du Mans, Hôpital d'instruction des Armées Percy, Centre Hospitalier de Béziers, Centre Hospitalier de Niort, Centre Hospitalier de l'Agglomération de Nevers, Centre Hospitalier Vétérinaire Frégis, Hôpital Paris Saint-Joseph, Intergroupe Francophone de Cancérologie Thoracique, Centre Hospitalier Universitaire de Caen Normandie
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2166957839
